dabigatran has been researched along with Ischemic Stroke in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 40 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, Y; Gong, Y; Hu, K; Jiang, J; Liu, Z; Ma, L; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhang, H; Zhou, S | 1 |
| Aoyama, T; Enomoto, A; Kawano, Y; Mano, Y; Nagata, M; Nishikawa, T; Sasaki, Y; Takahashi, H | 1 |
| Gerner, ST; Kallmünzer, B; Macha, K; Plechschmidt, J; Schwab, S; Siedler, G; Stoll, S; Strasser, E; Wang, R | 1 |
| Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L | 1 |
| Akhmatkhanova, LK; Cheboksarov, DV; Khamidova, LT; Klychnikova, EV; Kokov, LS; Kovaleva, EA; Muslimov, RS; Petrikov, SS; Ramazanov, GR; Rybalko, NV; Shamalov, NA | 1 |
| Archontakis-Barakakis, P; Batsidis, A; Giamouzis, G; Giannakoulas, G; Giannopoulos, S; Kalaitzoglou, D; Kokkinidis, DG; Li, W; Lip, GYH; Manolopoulos, A; Ntaios, G; Palaiodimos, L; Tzelves, L | 1 |
| Al Kasasbeh, M; Al-Abdouh, A; Barbarawi, M; Barbarawi, O; Corcoran, J; Mhanna, M; Obeidat, K; Pickett, CC | 1 |
| Chaudhury, P; Desai, MY; Harb, S; Johnston, D; Kapadia, S; Menon, V; Mentias, A; Michael, M; Nakhla, S; Saad, M; Saliba, W; Svensson, L; Wazni, O | 1 |
| Chiba, T; Egashira, S; Ihara, M; Inoue, M; Kimura, S; Koga, M; Okada, T; Shiozawa, M; Takashima, H; Toyoda, K; Wada, S; Yoshimoto, T; Yoshimura, S | 1 |
| Bakuła, E; Bednarski, J; Bil, J; Błaszczyk, R; Gawałko, M; Gorczyca-Głowacka, I; Jelonek, O; Kapłon-Cieślicka, A; Krzciuk, M; Krzesiński, P; Kuźma, Ł; Mamcarz, A; Rajtar-Salwa, R; Szpotowicz, A; Szyszkowska, A; Tokarek, T; Tomaszuk-Kazberuk, A; Uziębło-Życzkowska, B; Wełnicki, M; Wójcik, M; Wojewódzki, M; Wożakowska-Kapłon, B | 1 |
| Baborikina, A; Haritoncenko, I; Karelis, G; Kikule, I | 1 |
| Brewster, J; Hingorani, AD; Lau, WCY; Li, J; Lip, GYH; Man, KKC; Reich, C; Seager, S; Stewart, HM; Torre, CO; Van Zandt, M; Wei, L; Wong, ICK | 1 |
| Frol, S; Kermer, P; Oblak, JP; Šabovič, M | 1 |
| Aronow, HD; Hume, AL; Lawal, OD; Matson, KL; Shobayo, F; Taveira, TH; Wen, X; Zhang, Y | 1 |
| Desai, NR; Dhruva, SS; Graham, DJ; Inselman, JW; Lee, JY; Ngufor, C; Noseworthy, PA; Polley, E; Ross, JS; Shah, ND; Siontis, KC; Yao, X | 1 |
| Bessette, LG; Bykov, K; Cervone, A; Kim, DH; Lin, KJ; Mastrorilli, JM; Singer, DE | 1 |
| Andreone, V; Anticoli, S; Barbarini, L; Biguzzi, S; Caggiula, M; Candelaresi, P; Caso, V; Cenciarelli, S; Colangeli, E; Concari, L; Cordici, F; De Angelis, MV; Dell'Aera, C; Diana, F; Digiovanni, A; Eusebi, P; Fortunata Musolino, R; Gentile, M; Giammello, F; Giannandrea, D; Giorli, E; La Gioia, S; Longoni, M; Mangiardi, M; Matteo, E; Migliaccio, L; Mosconi, MG; Muto, M; Naccarato, M; Paciaroni, M; Petruzzellis, M; Pronello, E; Ricci, S; Rizzo, F; Romoli, M; Ruggiero, M; Sacco, S; Scura, GM; Sepe, FN; Sessa, M; Toni, D; Zedde, ML; Zini, A | 1 |
| Kwon, HM; Lee, YS; Moon, HS; Nam, KW; Won, SH | 1 |
| Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E | 1 |
| Chu, CL; Dai, JW; Liao, SC; Wang, CH | 1 |
| Brinkmann, M; Diener, HC; Eschenfelder, CC; Gröschel, K; Grosse, GM; Hüsing, A; Kuklik, N; Michalski, D; Nabavi, D; Poli, S; Royl, G; Sparenberg, P; Stang, A; Weimar, C; Weissenborn, K | 1 |
| Chen, K; Chen, X; Chen, Z; Ju, J; Li, Q; Ma, D; Tian, W; Wang, T; Wang, X; Xu, H; Zhang, J | 1 |
| Ago, T; Kitayama, J; Ogata, T; Okata, T; Wakisaka, Y; Yoshioka, T | 1 |
| Chang, YM; Chen, CH; Hsieh, MT; Lin, PY; Lin, SH; Liu, CH; Sung, PS; Wang, CM | 1 |
| Abdalla, Y; Abraham, A; Althaus, K; Becks, G; Berrouschot, J; Berthel, J; Bode, FJ; Burghaus, L; Cangür, H; Daffertshofer, M; Diener, HC; Edelbusch, S; Eggers, J; El-Sabassy, H; Eschenfelder, CC; Gerlach, R; Grond, M; Gröschel, K; Große-Dresselhaus, F; Günther, A; Haase, CG; Haensch, CA; Harloff, A; Heckmann, JG; Held, V; Hieber, M; Kauert, A; Kermer, P; Kern, R; Kerz, T; Köhrmann, M; Kraft, P; Kühnlein, P; Latta, J; Leinisch, E; Leithner, C; Lenz, A; Mäurer, M; Müllges, W; Neumann-Haefelin, T; Nolte, CH; Obermann, M; Partowi, S; Patzschke, P; Poli, S; Pulkowski, U; Purrucker, J; Rehfeldt, T; Ringleb, PA; Rossi, R; Röther, J; Sarnowksi, BV; Sauer, O; Schackert, G; Schäfer, N; Schellinger, PD; Schneider, A; Schuppner, R; Schwab, S; Schwarte, O; Seitz, RJ; Senger, S; Shah, YP; Sindern, E; Sparenberg, P; Steiner, T; Szabo, K; Urbanek, C; Weissenborn, K; Wienecke, P; Witt, K; Wruck, R; Wunderlich, S | 1 |
| Agosti, S; Di Brigida, G; Morelli, N; Risso, R; Rota, E; Rovere, ME; Testa, L | 1 |
| Alrohimi, A; Buck, B; Butcher, K; Dowlatshahi, D; Kalashyan, H; Ng, K; Shamy, M; Sharma, M; Shuaib, A; Sivakumar, L; Stotts, G; Thirunavukkarasu, S | 1 |
| Ahmed, N; Barbarini, L; Escudero-Martinez, I; Fryze, W; Gdovinova, Z; Karlinski, M; Kobayashi, A; Krastev, G; Lesko, N; Mazya, M; Paiva Nunes, A; Pasztoova, K; Peeters, A; Sobolewski, P; Teutsch, C; Toni, D; Vilionskis, A | 1 |
| Bonetti, B; Bovi, P; Bovi, T; Cappellari, M; Forlivesi, S; Micheletti, N; Musso, AM; Sajeva, G; Tomelleri, G; Valbusa, V; Zucchella, C | 1 |
| Haas, S; Patti, G | 1 |
| Cho, HJ; Choi, HY; Choi, S; Jang, HJ; Jang, SS; Jeon, S; Kim, DE; Kim, H; Kim, J; Kim, K; Kim, YD; Kwon, IC; Lee, KY; Lee, SK; Nahrendorf, M; Ryu, WS; Schellingerhout, D | 1 |
| Chao, TF; Chen, SJ; Chen, TJ; Jiang, YR; Liao, JN; Tsai, CT | 1 |
| Basu, S; Brown, JD; Cristofoletti, R; Fang, LL; Farhan, N; Jiang, S; Kim, S; Lesko, LJ; Lingineni, K; Schmidt, S | 1 |
| Chutinet, A; Diener, HC; Easton, JD; Granger, CB; Kleine, E; Marquardt, L; Meyerhoff, J; Sacco, RL; Zini, A | 1 |
| Frol, S; Hudnik, LK; Oblak, JP; Šabovič, M; Sernec, LP | 1 |
| Beharry, JM; Hanger, HC; Mee, HJ; Wilkinson, TJ; Wu, TY | 1 |
| Barnes, GD; Cuker, A; Dawwas, GK; Dietrich, E; Leonard, CE; Lewis, JD | 1 |
| de Brouwer, B; Egea, M; Eggington, S; Franco, N; Huynh, M; Ismyrloglou, E; Joglekar, R; Liu, S; Lyon, J; Reynolds, MR; Rosemas, SC; Thijs, V; Tsintzos, SI; Tsivgoulis, G; Witte, KK; Ziegler, PD | 1 |
| Han, KD; Kim, BS; Kim, HK; Kim, YJ; Lee, H; Lee, HJ; Lee, SP; Park, JB | 1 |
| Abenhaim, L; Benichou, J; Davy, JM; Dialla, O; Ferrières, J; Grimaldi-Bensouda, L; Le Heuzey, JY; Leys, D; Martinez, M; Nighoghossian, N; Nordon, C; Smadja, D; Touzé, E | 1 |
7 review(s) available for dabigatran and Ischemic Stroke
| Article | Year |
|---|---|
Comparison of non-vitamin K antagonist oral anticoagulants on bleeding and thrombosis.
Topics: Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Stroke; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis | 2021 |
Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Intracranial Hemorrhages; Ischemic Stroke; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2022 |
Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Nonvalvular Atrial Fibrillation and Cancer: A Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Ischemic Stroke; Neoplasms; Network Meta-Analysis; Stroke; Treatment Outcome; Warfarin | 2022 |
Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke.
Topics: Antithrombins; Dabigatran; Hemorrhagic Stroke; Humans; Intracranial Hemorrhages; Ischemic Stroke; Stroke | 2023 |
Thrombolysis after dabigatran reversal: A nation-wide Italian multicentre study, systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Brain Ischemia; Dabigatran; Humans; Intracranial Hemorrhages; Ischemic Stroke; Multicenter Studies as Topic; Observational Studies as Topic; Stroke; Thrombolytic Therapy | 2023 |
Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Network Meta-Analysis; Rivaroxaban; Stroke; Warfarin | 2023 |
Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Stroke; Male; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome | 2020 |
2 trial(s) available for dabigatran and Ischemic Stroke
| Article | Year |
|---|---|
Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study.
Topics: Aspirin; Dabigatran; Foramen Ovale, Patent; Humans; Ischemic Stroke; Prospective Studies; Recurrence; Risk Factors; Secondary Prevention; Stroke | 2022 |
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Dabigatran; Double-Blind Method; Embolic Stroke; Embolism; Female; Foramen Ovale, Patent; Humans; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Young Adult | 2021 |
31 other study(ies) available for dabigatran and Ischemic Stroke
| Article | Year |
|---|---|
Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Japan; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles | 2021 |
Monitoring of direct oral anticoagulants plasma levels for secondary stroke prevention.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Ischemic Stroke; Male; Pyridones; Rivaroxaban; Stroke | 2022 |
[First case of thrombolysis with non-immunogenic staphylokinase in a patient with ischemic stroke receiving dabigatran etexilate followed by thrombectomy].
Topics: Anticoagulants; Brain Ischemia; Dabigatran; Fibrinolytic Agents; Humans; Ischemic Stroke; Metalloendopeptidases; Stroke; Thrombectomy; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2022 |
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Intravenous Thrombolysis With Alteplase at 0.6 mg/kg in Patients With Ischemic Stroke Taking Direct Oral Anticoagulants.
Topics: Administration, Intravenous; Aged; Anticoagulants; Dabigatran; Female; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Rivaroxaban; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2022 |
Do Patients with Atrial Fibrillation and a History of Ischemic Stroke Overuse Reduced Doses of NOACs?-Results of the Polish Atrial Fibrillation (POL-AF) Registry.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Ischemic Stroke; Poland; Prospective Studies; Pyridones; Registries; Rivaroxaban | 2022 |
Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy.
Topics: Aged; Aged, 80 and over; Antidotes; Antithrombins; Dabigatran; Female; Humans; Ischemic Stroke; Male; Retrospective Studies; Stroke; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2022 |
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Cohort Studies; Dabigatran; Embolism; Humans; Ischemic Stroke; Renal Insufficiency, Chronic; Rivaroxaban; United States | 2022 |
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Liver Diseases; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Ischemic Stroke; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Dementia; Female; Hemorrhage; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; United States; Warfarin | 2023 |
Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thromboembolism; Vitamin K; Warfarin | 2023 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Flecainide; Hemorrhage; Hospitalization; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; Sotalol; Stroke; United States | 2023 |
Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials.
Topics: Antithrombins; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Retrospective Studies; Thromboembolism | 2023 |
Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Ischemic Stroke; Prospective Studies; Stroke; Vitamins | 2023 |
[A case of recurrent stroke with carotid-web despite dabigatran treatment successfully treated by carotid endarterectomy].
Topics: Adult; Carotid Arteries; Cerebral Infarction; Dabigatran; Endarterectomy, Carotid; Female; Humans; Ischemic Stroke; Stroke | 2023 |
Comparing Efficacy and Safety Between Patients With Atrial Fibrillation Taking Direct Oral Anticoagulants or Warfarin After Direct Oral Anticoagulant Failure.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Stroke; Subarachnoid Hemorrhage; Vitamin K; Warfarin | 2023 |
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Brain Ischemia; Dabigatran; Germany; Humans; Intracranial Hemorrhages; Ischemic Stroke; Retrospective Studies; Stroke; Thrombolytic Therapy | 2020 |
The management of patients with acute ischemic stroke while on direct oral anticoagulants (DOACs): data from an Italian cohort and a proposed algorithm.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Disease Management; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Ischemic Stroke; Italy; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2020 |
Early Dabigatran Treatment After Transient Ischemic Attack and Minor Ischemic Stroke Does Not Result in Hemorrhagic Transformation.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Dabigatran; Humans; Ischemic Attack, Transient; Ischemic Stroke; Middle Aged; Prospective Studies; Stroke; Treatment Outcome; United States | 2020 |
Dabigatran initiation in patients with non-valvular AF and first acute ischaemic stroke: a retrospective observational study from the SITS registry.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Humans; Ischemic Stroke; Male; Registries; Retrospective Studies; Stroke | 2020 |
Factors influencing cognitive performance after 1-year treatment with direct oral anticoagulant in patients with atrial fibrillation and previous ischemic stroke: a pilot study.
Topics: Aged; Atrial Fibrillation; Cognition; Dabigatran; Dementia; Duration of Therapy; Factor Xa Inhibitors; Female; Heart Failure; Humans; Hyperlipidemias; Ischemic Stroke; Italy; Male; Myocardial Ischemia; Neuropsychological Tests; Prognosis; Risk Factors | 2021 |
Short-Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State.
Topics: Aged; Aged, 80 and over; Animals; Antithrombins; Arachidonic Acid; Aspirin; Carotid Artery Thrombosis; Cerebral Infarction; Chlorides; Computed Tomography Angiography; Dabigatran; Deprescriptions; Factor Xa Inhibitors; Female; Ferric Compounds; Humans; Ischemic Stroke; Magnetic Resonance Angiography; Male; Mean Platelet Volume; Mice; Noxae; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Substance Withdrawal Syndrome; Thrombin; Thrombophilia; X-Ray Microtomography | 2021 |
Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Mortality; Propensity Score; Pyrazoles; Pyridones; Stroke; Warfarin | 2021 |
Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate.
Topics: Antithrombins; Biological Availability; Chemical Precipitation; Dabigatran; Drug Compounding; Drug Development; Drug Substitution; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Stroke; Pharmacokinetics; Safety; Treatment Outcome | 2021 |
Idarucizumab Reversal of Dabigatran in Patients with Acute Ischemic Stroke and Intracranial Hemorrhage: Comparison with Non-idarucizumab-Treated Patients.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome | 2021 |
Anticoagulant-related intracranial haemorrhage: time to anticoagulant reversal improving but still slower than thrombolysis for ischaemic stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Dabigatran; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Ischemic Stroke; Male; Middle Aged; New Zealand; Retrospective Studies; Thrombolytic Therapy; Time Factors; Treatment Outcome; Warfarin | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Comparative Effectiveness Research; Dabigatran; Embolism; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Ischemic Stroke; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Treatment Outcome; Warfarin | 2021 |
Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolic Stroke; Hemorrhage; Humans; Ischemic Stroke; Models, Economic; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Time Factors; Treatment Outcome | 2021 |
Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Ischemic Stroke; Male; Middle Aged; Proton Pump Inhibitors; Republic of Korea; Risk; Rivaroxaban; Upper Gastrointestinal Tract; Warfarin | 2021 |
Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Dabigatran; Female; Heart Disease Risk Factors; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Middle Aged; Risk Factors; Stroke; Treatment Outcome; Vitamin K | 2021 |